title: [Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage].
abstract: OBJECTIVE
  To evaluate the efficacy of Remaxol used to treat post-withdrawal disorders in alcoholic patients with comorbid liver damage.
  
  
  METHODS
  The authors assessed the severity of clinical parameters, such as pathological craving and anhedonia, biochemical parameters (bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) in 120 patients aged 30-60 years in the stage of remission formation. The patients were divided into two groups: 1) 62 patients received Remaxol; 2) 58 persons took placebo (a comparative group).
  
  
  RESULTS
  The use of the drug caused an accelerated reduction in somato-autonomic symptoms and a decrease in affective strain and manifestations of anxiety with disactualization of a pathological alcohol craving ideator. The patients receiving remaxol showed a prompt improvement in some biochemical parameters: the levels of total and direct bilirubin halved; in Group 1, the multiplicity of a decrease in ALT and AST activities was 2.5 and 2.2 times versus 1.38 and 1.47 in Group 2. After the course of therapy, the symptoms of anhedonia diminished by 5.2 times in Group 1 and only by 2.4 times in Group 2.
  
  
  CONCLUSIONS
  The positive changes induced by remaxol incorporated into the combination treatment are due to the polymodal effect of the drug on metabolic mechanisms in both the nervous system and liver. This double action promotes the increased efficiency of treatment and the creation of conditions for remission.
authors.forename: N A
authors.initials: NA
authors.lastname: Bokhan
authors.forename: A F
authors.initials: AF
authors.lastname: Abolonin
authors.forename: I É
authors.initials: IÉ
authors.lastname: Ankudinova
authors.forename: D I
authors.initials: DI
authors.lastname: Kurgak
authors.forename: A I
authors.initials: AI
authors.lastname: Mandel'
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000201:enzymology / Q000453:epidemiology; D015897:Comorbidity; D004359:Drug Therapy, Combination; D006801:Humans; D007262:Infusions, Intravenous; D008099:Liver / Q000201:enzymology / Q000473:pathology*; D008107:Liver Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology; D008108:Liver Diseases, Alcoholic / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D013386:Succinates / Q000008:administration & dosage*; D014149:Tranquilizing Agents / Q000627:therapeutic use; D016896:Treatment Outcome; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D010276:Parasympatholytics; C555877:Remaxol; D013386:Succinates; D014149:Tranquilizing Agents; D014815:Vitamins